All News
Filter News
Found 233 articles
-
Sling Therapeutics Appoints Faheem Hasnain as Chairman of the Board of Directors
6/27/2022
Sling Therapeutics, Inc., today announced the appointment of Faheem Hasnain as chairman of the company's Board of Directors.
-
There were multiple leadership changes in the biopharma industry, with several new chief executive officers tapped to guide companies through their next growth phases.
-
Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer
6/23/2022
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company.
-
Biotech Firm Tackling COVID-19 and M. bovis Announces Successful Development of Rapid, Accurate Johne’s Disease Assay
6/13/2022
Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test for Mycobacterium avium paratuberculosis – also known as Johne’s disease, that could save the New Zealand dairy industry upwards of $80 million a year in lost production.
-
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
6/3/2022
Celularity Inc., a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, announced the appointment of Diane Parks to its Board of Directors.
-
Kura Oncology to Participate in Three Upcoming Investor Conferences in June 2022
5/26/2022
Kura Oncology, Inc. announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:
-
Exo Therapeutics Appoints Stephanos Ioannidis as Executive Vice President, Drug Discovery and Catherine Scholz as Senior Vice President, Program Management
5/17/2022
Exo Therapeutics, Inc. , a company pioneering the discovery and development of small molecules that can reprogram protein targets through binding to exosites, today announced the appointments of Stephanos Ioannidis, PhD, as Executive Vice President, Drug Discovery and Catherine Scholz, PharmD, as Senior Vice President, Program Management.
-
Kura Oncology Reports First Quarter 2022 Financial Results
5/4/2022
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported first quarter 2022 financial results and provided a corporate update.
-
Kura Oncology to Report First Quarter 2022 Financial Results
4/27/2022
Kura Oncology, Inc. today announced that it will report first quarter 2022 financial results after the close of U.S. financial markets on Wednesday, May 4, 2022.
-
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting– Presentations to highlight significant opportunities targeting farnesyl transferase inhibition –
3/8/2022
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans from April 8-13, 2022.
-
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
3/1/2022
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights.
-
Kura Oncology to Participate in Two Upcoming Investor Conferences - Feb 28, 2022
2/28/2022
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences.
-
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
2/24/2022
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported fourth quarter and full year 2021 financial results and provided a corporate update.
-
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
2/17/2022
Kura Oncology, Inc. today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022.
-
Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
2/10/2022
Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference.
-
Kura Oncology Expands Leadership Team with Key Promotions
2/1/2022
Kura Oncology, Inc. announced the expansion of its leadership team with three promotions: Mollie Leoni, M.D., to Senior Vice President, Clinical Development, Pete De Spain to Senior Vice President, Investor Relations and Corporate Communications, and Tom Doyle to Senior Vice President, Finance and Accounting.
-
The FDA has lifted the partial hold on Kura Oncology's KOMET-001 Phase IB trial on a potential treatment for acute myeloid leukemia.
-
Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia
1/20/2022
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML).
-
Exo Therapeutics Appoints Antonio Gualberto as President of Research & Development and Chief Medical Officer
1/18/2022
Exo Therapeutics, Inc. today announced the appointment of Antonio Gualberto, MD, PhD, as President of Research & Development and Chief Medical Officer.
-
PMV Pharma Announces Changes to its Board of Directors
1/6/2022
PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, announced the appointment of Kirsten Flowers to its Board of Directors.